However, this approach is being revisited after preclinical studies have shown that concurrent targeting of these epitopes with the bispecific zanidatamab induced higher levels of HER2 inhibition and anti-tumour activity compared to trastuzumab and pertuzumab [60]. The gene discussed is ERBB2; the disease is neoplasm.